Skip to main content
. 2013 Nov 18;31(36):4529–4535. doi: 10.1200/JCO.2013.49.0086

Fig 2.

Fig 2.

(A) The median time to progression (TTP) of patients achieving at least a complete response (CR; n = 146; 33%) is 39 months (95% CI, 33 to 48) compared with 20 (95% CI, 17 to 22), 17 (95% CI, 14 to 21), and 18 (95% CI, 9 to 25) months, respectively, for those achieving very good partial response (VGPR; including near complete response [nCR] as per International Myeloma Working Group definition; n = 151; 34%), partial response (PR; n = 109; 24%), and stable disease (SD; n = 21; 5%). Patients with progressive disease (PD; n = 18; 4%) had a short median TTP of 3 months (95% CI, 2.7 to 4). (B) Median TTP of patients achieving stringent complete response (sCR; n = 109) is 50 months (4.2 years; 95% CI, 36 to 63 months) compared with 20 months (1.7 years; 95% CI,15 to 36) and 19 months (1.6 years; 95% CI, 16 to 22 months) for groups attaining CR (n = 37) and nCR (n = 91), respectively (P < .001).